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Abstract.
Background: Although hydromethylthionine is a potent tau aggregation inhibitor, no difference was found in either of two
Phase III trials in mild to moderate Alzheimer’s disease (AD) comparing doses in the range 150–250 mg/day with 8 mg/day
intended as a control.
Objective: To determine how drug exposure is related to treatment response.
Methods: A sensitive plasma assay for the drug was used in a population pharmacokinetic analysis of samples from 1,162
of the 1,686 patients who participated in either of the Phase III trials with available samples and efficacy outcome data.
Results: There are steep concentration-response relationships for steady state plasma levels in the range 0.3–0.8 ng/ml at the
8 mg/day dose. Using a threshold based on the lower limit of quantitation of the assay on Day 1, there are highly significant
differences in cognitive decline and brain atrophy in patients with above threshold plasma levels, both for monotherapy and
add-on therapy, but with effect sizes reduced by half as add-on. Plasma concentrations in the range 4–21 ng/ml produced by
the high doses are not associated with any additional benefit.
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Conclusions: Hydromethylthionine has pharmacological activity on brain structure and function at the 8 mg/day dose as
monotherapy or as add-on to symptomatic treatments. This combined with a plateau at higher doses is consistent with the
lack of dose-response seen in the Phase III trials. Treatment benefit is predicted to be maximal at 16 mg/day as monotherapy.
A placebo-controlled trial in mild/moderate AD is now ongoing to confirm efficacy at this dose.
Keywords: Acetylcholinesterase inhibitor, Alzheimer’s disease, clinical trials, drug interaction, leucomethylthioninium,
population pharmacokinetics, hydromethylthionine
INTRODUCTION
Alzheimer’s disease (AD) is an irreversible neu-
rodegenerative disease affecting as many as 1 in
5 of the population over the age of 65 years.
The only approved treatments are symptomatic.
The most widely used of these are the acetyl-
cholinesterase inhibitors (AChEIs) which work by
chronically increasing the levels of acetylcholine in
the synaptic cleft. In experimental models, cholin-
ergic function is associated primarily with selective
attention [1–3], and is not particularly sensitive to
more broadly based measures of functional impair-
ment/improvement (reviewed in [4, 5]). Similar
considerations apply to memantine, which also mod-
ulates brain function in a non-specific manner [6, 7].
Although the small therapeutic benefit of these treat-
ments persists, over time, patients continue to decline
at the untreated rate [8], with fewer than 30% of
patients continuing on AChEIs 12 months after initi-
ation [9–11]. A substantial proportion of AD patients
are not treated,∼44% in the US [12] and∼77% in UK
[13]. In France, reimbursement for these drugs has
been withdrawn because of “insufficient medical ben-
efit and dangerousness because of side effects” [14].
Hence it is agreed generally that a major unmet med-
ical need exists to develop a treatment able to slow
the progression of AD. A Lancet Neurology Com-
mission report noted that “ . . . no treatment is yet
available to halt or reverse the underlying pathology
of established AD. Indeed, an effective therapy for
AD is perhaps the greatest unmet need facing modern
medicine” [15].
From 2002 to 2012, there were 289 clinical trials
at Phase II or Phase III, with an overall failure rate of
99.6% [16], and a further 19 trial failures since 2012
targeting various aspects of pathological processing
of amyloid- [17]. There is now increasing recogni-
tion of the importance of tau aggregation pathology
as an important substrate of clinical dementia and as
a target for therapy [18]. The most advanced late-
stage program targeting tau aggregation currently
in development is based on leuco-methylthioninium
bis(hydromethanesulphonate) (LMTM) [19]. LMTM
has recently been assigned the International Nonpro-
prietary Name “hydromethylthionine”, recognizing
it as chemically and pharmacologically distinct from
methylthioninium chloride (MTC, methylene blue).
The methylthioninium (MT) moiety can exist in oxi-
dized (MT+) and reduced (LMT) forms. LMTM
is a stabilized dihydromesylate salt of LMT which
has more favorable pharmaceutical properties than
the oxidized MT+ form administered as MTC [19,
20]. We have retained the LMTM abbreviation in
the present paper as it facilitates technical discus-
sion of the distinctive properties of LMT. LMT, and
not MT+, is the active species that blocks tau aggre-
gation in vitro acting at a tau:LMT molar ratio of
1 : 0.1 [21]. In earlier studies, the MT moiety was
also found to reverse the proteolytic stability of tangle
filaments isolated from AD brain tissues at a simi-
lar molar ratio [19, 22]. It is therefore a potent tau
aggregation inhibitor with a site of action within the
proteolytically stable core tau unit of the tangle fil-
ament [23–25]. LMT also blocks tau aggregation in
cell-based assays [19, 21] and reduces tau aggrega-
tion pathology and associated behavioral deficits in
tau transgenic mouse models in vivo at a dose of
9 mg/kg/day [26]. This corresponds approximately
to a human dose of 8–16 mg/day in terms of plasma
Cmax considering that the half-life in mice is 4 h com-
pared with 37 h in elderly humans.
The MT moiety also has a range of other properties
that affect cellular metabolism. It has been known for
some time that it enhances mitochondrial activity at
low concentrations (10–100 nM) by acting as a sup-
plementary electron carrier in the electron transfer
chain [27, 28]. It is able to induce mitochondrial bio-
genesis and to activate Nrf2-mediated oxidative stress
response elements in vivo [29]. Other potentially
beneficial activities include neuroprotective effects
in the brain by inhibiting microglial activation [30]
and enhancing autophagy at the 10–20 nM concen-
tration range [30, 31]. In a more recent study in
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a tau transgenic mouse model for AD, LMTM at
doses of 5 and 15 mg/kg/day was found to increase
acetylcholine levels in hippocampus, restore choline
acetyltransferase activity in basal forebrain, reverse
impairment in glutamate release from brain synap-
tosomes and increase Complex IV activity in brain
mitochondria [32]. Therefore, in addition to preven-
tion and dissolution of AD tau aggregates [19, 22],
LMTM has numerous complementary actions which
address many of the pathways currently advocated as
having potential for the treatment of AD [33, 34].
Given these potentially useful pharmacological
properties, it was surprising that LMTM failed to
show any difference in two Phase III trials in which
patients were randomized to compare doses in the
range 150–250 mg/day with a low dose (8 mg/day)
that was intended as a control to mask the variable
discoloration of urine that can occur on exposure
to air following excretion [35, 36]. The high doses
were selected on the basis of an earlier placebo-
controlled dose-finding Phase II study which showed
that the minimum effective dose is 138 mg/day for
MTC, and early comparative pharmacokinetic (PK)
studies showing similar plasma levels of total MT
measured after acid extraction of samples [37]. How-
ever, we have found that this assay is dominated
by an acid-labile inactive conjugate of LMT in
plasma and this is not distinguished from the active
parent form of the drug. We have developed a sen-
sitive assay which can measure parent MT levels in
plasma, and which has been found to be reliable and
accurate in five Phase I studies and 14 preclinical
studies.
We have used this assay to measure blood sam-
ples collected from patients participating in the two
Phase III trials to determine the extent to which
drug exposure determines treatment response on clin-
ical and MRI volumetric endpoints. If there is any
concentration-response relationship, then the further
objectives were to explore how co-medication status
with treatments approved for AD and drug expo-
sure interact in terms of plasma levels and treatment
response, and to determine the most suitable dose
for testing in a further randomized placebo-controlled
trial.
MATERIALS AND METHODS
Study patients
Pharmacokinetic analyses were undertaken using
plasma concentration data from patients who par-
ticipated in either of two completed Phase III trials
which have been described previously [35, 36]. In
brief, the first (TRx-237-015) was a 15-month study
which recruited 890 patients from 115 sites across 16
countries in EU, North America, Asia, and Russia.
Patients had to be <90 years of age and have a diag-
nosis of mild to moderate probable AD according to
National Institute of Aging (NIA) and Alzheimer’s
Association (AA) criteria [38] and a Mini-Mental
State Examination (MMSE) score of 14–26 inclu-
sive and with a Clinical Dementia Rating (CDR) total
score of 1 or 2. The second study (TRx-237-005)
was an 18-month trial which recruited 800 patients
from 108 sites in Canada, United States, Australia,
and Europe. Patients had to meet the same age and
diagnosis criteria, except that they were required
to have a MMSE score of 20–26 inclusive and a
CDR total score of 0.5 or 1.0. Concomitant use of
AChEIs or memantine (or both) was permitted in
both studies provided this was at a stable dose for
at least 18 weeks before randomization. Concomi-
tant use of serotonergic antidepressant, antipsychotic
(except clozapine or olanzapine), and sedative med-
ications was also permitted at stable doses where
clinically feasible. Patients were randomly assigned
to receive LMTM at doses of 250, 150, or 8 mg/day
in Study 015 and doses of 200 or 8 mg/day in
Study TRx-237-005. Randomization in both stud-
ies was stratified according to geographical region,
use of AD-labelled co-medications, and severity of
AD. The co-primary outcomes in both studies were
the Alzheimer’s Disease Assessment Scale–cognitive
subscale, 11-item version (ADAS-cog11) and the
Alzheimer’s Disease Co-operative Study–Activities
of Daily Living, 23-item version (ADCS-ADL23)
scale measured at baseline and every 3 months. MRI
scans were undertaken at screening or baseline and
at 3-month intervals. MRI acquisition protocol and
parameters were standardized across sites and all
data were centrally collected, quality-controlled, and
analyzed blind by an imaging core lab (Bioclinica).
Volumetric data were used to measure changes in
whole brain volume (WBV, which provides a measure
of the volume of grey and white matter), lateral ven-
tricular volume (LVV), and other regional volumes
including hippocampus, although only the global
measures are reported in the present study. Base-
line volumes were assessed using FreeSurfer 5.3, and
volume change was assessed using Boundary Shift
Integral and Tensor Based Morphometry for regional
structures. Full details and study protocols for these
two trials are available [35, 36].
934 B.O. Schelter et al. / LMTM Reduces AD Clinical Decline and Brain Atrophy
Plasma levels
Blood samples for assessment of parent MT, N-
desmethyl MT, and total MT (sum of parent MT
and a labile LMT conjugate) were collected from
each patient on the first treatment visit (two sam-
ples: pre-dose and approximately 3.5 h after the dose)
and at each subsequent on-treatment visit. The pro-
tocol specified that PK plasma sampling was to
be conducted only at sites with adequate facilities
(i.e., a refrigerated centrifuge and adequate capabil-
ity to reliably freeze samples). Blinded analyses were
conducted at the University of Aberdeen GLP Test
Facility. MT levels in plasma were measured using
liquid chromatography-tandem mass spectrometry.
The MT moiety is ionized by the mass spectroscopy
procedure and hence LMT and MT+ forms in plasma
cannot be discriminated. The method was validated
for use in the Phase III studies over the range 0.2
to 10 ng/ml. Extrapolated MT concentrations were
available below the lower limit of quantitation (but
above the lower limit of detection) in approximately
35% of the Day 1 patients randomized to the 8 mg/day
dose. The method was validated for long-term sam-
ple storage of 162 days at –20◦C. Data from samples
stored for longer periods (up to 827 days) were found
to produce somewhat higher levels systematically, but
the conditional weighted residuals overlapped sub-
stantially, indicating that the overall precision was
similar and that modifications to the pharmacokinetic
model to take account of storage time were not nec-
essary. Plasma samples from a total of 1,296 patients
from the two Phase III studies in AD were available
for analysis and, of these, 1,162 also had baseline
and post-baseline efficacy outcome data available for
analysis.
Pharmacokinetic model
The development and validation of the pharma-
cokinetic model was undertaken independently by
the Institute of Clinical Pharmacodynamics (ICPD,
New York, US) and will be reported separately. It
was developed in two stages based on data from
four Phase I studies in healthy volunteers and in
special populations of patients with renal or hep-
atic impairment covering doses ranging from 4 mg to
1000 mg of MT given as LMTM. The initial model
accounted for all forms of MT measured. A simplified
model restricted to parent MT concentration data was
found to have equivalent accuracy for the descrip-
tion of results from a repeat-dose Phase I study of
LMTM over the relevant dosing range. For reasons
of computational convenience, the simplified model
was used for the Phase III population PK analyses to
permit per-subject parameter estimation. Application
of the model to the observed parent MT concentra-
tions from the Phase III studies was dependent on
the availability of exact date and time of dosing rel-
ative to sample collection. This was recorded most
accurately for samples collected in clinic on Day
1. Data from post-Day 1 visits were available, but
the lack of precise timing of sample collection rel-
ative to last dose reduced their accuracy. Although
the results were directionally comparable to the more
precise Day 1 estimates, only the latter were used for
the exposure-response analyses reported here based
on the per-subject estimated steady state maximum
concentration of the drug (Cmax,ss). Renal function,
estimated using the Cockcroft-Gault equation for cre-
atinine clearance [39], was a significant term in the
model; age, weight, body mass index, albumin, and
other factors were not significant.
Statistical analyses
The exposure-response analyses were conducted
independently by ICPD and verified by TauRx. As a
first step in the analysis, the concentration-response
data were reviewed for ADAS-cog11 decline at week
65 in all patients receiving LMTM at a dose of
8 mg/day using a sigmoid Emax (maximum response)
model not requiring assumptions regarding exposure
subgroups. The model was fitted using covariates
geographical region, CDR at baseline, co-medication
status, and baseline ADAS-cog11. A 90% bootstrap
confidence interval was also calculated.
Having shown a concentration-dependent response
for cognitive decline, a mixed-effects model for
repeated measures analysis was used to characterize
further the relationship between each efficacy end-
point and parent MT plasma exposure (steady state
Cmax,ss) according to the following formula:
pharmacological activity ∼ plasma-level × visit
+ co-medication-status × visit + co-medication−
status × plasma-level + geographical-region+
CDR-at-baseline + baseline-score × visit
The following terms were categorical variables in
the models: plasma exposure (Cmax,ss) (7 levels),
visit (5 levels), co-medication status with AD drugs
(2 levels), geographical region (2 levels), and CDR
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at baseline (3 levels). For the longitudinal analyses,
plasma level was described by two levels (above or
below threshold).
In addition to the exposure-response analyses
described above, a further standard pharmacologi-
cal concentration-response analysis was undertaken
using the Hill equation [40] applied to the ADAS-
cog11 and whole brain volume data to characterize
the overall response profile quantitatively and to
investigate the lower concentration limit of the treat-
ment effect. The Hill equation was applied under
the assumption of non-cooperativity and was applied
with an additional linear term to permit trends occur-
ring at high concentrations to be included in the
model. The expanded Hill equation was applied to
the data in the form:
treatment response
= Emin −
(
Emax ×
(
Cmax, ss − Cmin
))/
(
EC50 +
(
Cmax, ss − Cmin
))
+ (A × (Cmax, ss − Cmin
))
where Emin and Cmin are imposed zero values
(assumed to be 11 ADAS-cog11 units or –30 cm3 for
WBV at 0.29 ng/ml based on visual inspection of the
data); E is the mean treatment response for any given
Cmax,ss subgroup; Emax is the maximum treatment
response as estimated from a standard Hill equation
without the additional linear term; EC50 is the Cmax,ss
at which the treatment response is 50% of the maxi-
mum response as estimated from the a standard Hill
equation without the additional term; A × (Cmax,ss –
Cmin) is a further linear term in which A is estimated
by the model to take account of the trends seen at
high concentrations. This was fitted separately for
LMTM added to approved symptomatic treatments
and for those who took the drug as monotherapy, with
parameters estimated using a non-linear least squares
estimator.
In order to relate Cmax,ss values to theoretical
doses, a linear model was fitted to the mean plasma
concentrations at the 8, 150, 200 and 250 mg/day
doses:
estimated dose = 22.22 × (Cmax, ss − 0.016
)
where dose is in mg/day and Cmax,ss is ng/ml units.
Trial registration
The TRx-237-005 trial is registered at Clinical-
trials.gov (NCT01689233) and the European Union
Clinical Trials Registry (21012-002847-28); and the
TRx-237-015 trial registered as NCT01689246 and
2012-002866-11.
Funding
The study was wholly sponsored by TauRx Thera-
peutics Ltd. (Singapore). The funder of the study took
the lead in study design, undertaking the study, data
interpretation, and initial drafting of the report.
RESULTS
The exposure-response relationship was first
examined for decline on the ADAS-cog11 scale over
65 weeks in patients receiving the 8 mg/day dose
using a sigmoid Emax analysis in which both the
plasma concentration and cognitive decline data sets
were included as continuous variables. As can be seen
from Fig. 1, there is a clear relationship between cog-
nitive decline and steady state plasma concentration
of the drug at the 8 mg/day dose.
This implies that LMTM at a dose of 8 mg/day has a
concentration-dependent effect on cognitive decline.
In order to examine this relationship further, patients
receiving LMTM at a dose of 8 mg/day were catego-
rized on the basis of the Cmax,ss into a low exposure
group defined by the percentage of patients with first
dose plasma levels below the level of quantitation
of the assay (0.2 ng/ml); this corresponds to a mod-
elled Cmax,ss below 0.373 ng/ml. There were 208 such
patients (35% of the 8 mg/day group). The remaining
Fig. 1. Sigmoid Emax analysis for ADAS-cog11 decline at week 65
with 90% bootstrap confidence intervals using estimated Cmax,ss
in patients receiving LMTM 8 mg/day.
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Table 1
Parent MT Cmax,ss for all patients with available plasma data
according to either plasma Cmax,ss subgroups (LMTM, 8 mg/day)
or dose (LMTM, 150–250 mg/day)
Dose groups n (%) Cmax,ss (ng/ml)
Mean (SD) Range
8 mg/day – Group 1 208 (35%) 0.334 (0.0251) 0.257–0.373
8 mg/day – Group 2 127 (21%) 0.393 (0.0125) 0.373–0.414
8 mg/day – Group 3 129 (22%) 0.449 (0.0189) 0.415–0.478
8 mg/day – Group 4 128 (22%) 0.565 (0.0810) 0.479–0.812
150 mg/day 188 (100%) 7.820 (1.787) 5.099–18.611
200 mg/day 329 (100%) 10.126 (2.374) 6.557–21.291
250 mg/day 187 (100%) 12.573 (2.460) 8.833–21.188
patients (N = 384) were split into three higher expo-
sure group terciles to permit better visualization of
trends (∼128 per group, 65% of patients receiving
the 8 mg/day dose). Patients receiving doses in the
range 150–250 mg/day were grouped according to
dose (N = 187–329 per group) (Table 1).
Plotting of least squares mean and standard error
estimates for change in ADAS-cog11, ADCS-ADL23,
LVV, and WBV for these groups confirmed that
clinical and volumetric outcomes all show sim-
ilar concentration-dependent relationships at the
8 mg/day dose (Fig. 2). The effects seen at the sub-
stantially higher plasma levels associated with doses
in the range 150–250 mg/day were no better than
those seen at the 8 mg/day dose in patients having
above-threshold plasma levels, consistent with the
absence of an overall dose-response relationship as
previously reported [35, 36].
Effect of LMTM co-medication with AChEI
and/or memantine
The exposure-response relationships for the same
plasma Cmax,ss subgroups (LMTM, 8 mg/day) or
dose (LMTM, 150–250 mg/day) were examined
separately according to co-medication status with
approved AD treatments (LMTM alone or added to
ongoing AChEI and/or memantine). As shown in
Fig. 3, the concentration-response profiles are similar
for LMTM as monotherapy and for add-on therapy,
although the pharmacological activity is reduced for
add-on therapy.
Pharmacological analysis of
concentration-dependent relationships for
cognitive decline and brain atrophy
The concentration-dependent relationships for
cognitive decline and loss of whole brain volume
were explored further using the Hill equation which
is commonly used in analyses of pharmacological
activity [40]. The plasma Cmax,ss subgroups (LMTM,
8 mg/day) or dose (LMTM, 150–250 mg/day) were
used but, since part of the aim was to permit better
estimation of the lower limit of the concentration-
response relationship, the 208 patients with Cmax,ss
less than 0.373 ng/ml were split further into two equal
groups of 104 patients (each representing 17% of the
overall LMTM 8 mg/day group); the models were
adjusted accordingly to 8 levels. Although plasma
levels on Day 1 in this latter group were below the
validated lower limit of quantitation of the assay,
drug was still detectable and could be quantified by
extrapolation from the assay calibration standards.
As can be seen from Fig. 4, the Hill equation
provides a good fit to the concentration-dependent
relationships for both cognitive decline and whole
brain atrophy. For both outcomes, the response func-
tions are consistent with a common lower limit of
drug activity at approximately 0.29 ng/ml for both
monotherapy and add-on therapy. Likewise, both
clinical and volumetric responses are predicted to
plateau above plasma levels corresponding to a the-
oretical dose of 16 mg/day. The maximum predicted
pharmacological activity for LMTM as add-on ther-
apy is about half that for monotherapy.
Binary outcome analyses based on Cmax,ss
threshold of 0.373 ng/ml
We undertook further exploratory analyses to com-
pare outcomes using patients with minimal drug
exposure (i.e., having Cmax,ss less than 0.373 ng/ml)
as a proxy for placebo. Statistical comparisons of
change in ADAS-cog11, ADCS-ADL23, LVV, and
WBV are first shown for all patients regardless
of co-medication status with approved AD drugs
(Table 2A). The same comparisons restricted to
patients taking the LMTM 8 mg/day dose are also
shown in Table 2B. There were highly signifi-
cant differences between the low and high plasma
Cmax,ss groups for all outcomes with the exception
of ADCS-ADL23. This is true whether all patients
are compared, or the analysis is restricted to patients
receiving the 8 mg/day LMTM dose.
The corresponding longitudinal trajectories over
65 weeks according to Cmax,ss above or below the
threshold value of 0.373 ng/ml are shown in Fig. 5.
The analyses were repeated taking account of co-
medication status with standard AD drugs for patients
receiving the 8 mg/day dose. As shown in Table 3 and
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Fig. 2. Model-derived least squares mean and standard error estimates of change over 65 weeks for clinical (a, b) and MRI volumetric
endpoints (c, d) according to plasma concentration group (8 mg/day) or dose (150–250 mg/day) for all patients irrespective of co-medication
status with AD-approved drugs.
3B, the same pattern of significant differences using
the 0.373 ng/ml threshold was seen whether patients
received LMTM at a dose of 8 mg/day as monother-
apy or as add-on to AD-approved treatments.
The corresponding longitudinal trajectories over
65 weeks are illustrated below for ADAS-cog11,
ADCS-ADL23, LVV, and WBV in Fig. 6.
Figure 4 suggests that the analysis using the
0.373 ng/ml threshold shown in Table 3A may under-
estimate the concentration-dependent difference in
activity in patients receiving LMTM as monother-
apy because of apparent activity even at the lowest
MT concentrations measured. We have therefore
undertaken a further analysis using patients taking
LMTM as add-on who had subthreshold plasma lev-
els as a common basis for comparison to examine
the effect of LMTM as monotherapy in patients
with above-threshold levels (Table 3C). As can be
seen by comparing Tables 3B and 3C, the apparent
exposure-dependent activity of LMTM as monother-
apy is approximately double that seen for LMTM
taken as add-on to standard treatments for all out-
comes, consistent with the Hill equation analysis
shown in Fig. 4.
Inﬂuence of choice of threshold and
intrinsic/extrinsic factors on plasma
concentration
As noted, the classification threshold we have
used in these analyses is based on the percentage of
patients with plasma levels below the validated limit
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Fig. 3. Model-derived least squares mean and standard error estimates of change over 65 weeks for clinical (a, b) and MRI volumetric
endpoints (c, d) according to plasma concentration group (8 mg/day) or dose (150–250 mg/day) split by co-medication status with AD-
approved drugs.
of the plasma assay on Day 1, and hence is indepen-
dent of the outcome analyses. However, we have also
examined the use of the median Cmax,ss value as the
cut-off for patients receiving the 8 mg/day dose as
an alternative unbiased threshold. As shown in Sup-
plementary Tables 1 and 2, the pattern of results is
essentially the same, although the estimated pharma-
cological activities are smaller due to inclusion of
more patients having some pharmacological activity
in the low exposure arm.
We also investigated the influence of a number of
intrinsic factors on Cmax,ss classification: age, weight,
body mass index, creatinine clearance, and serum
albumin level as well as baseline clinical character-
istics. Comparisons stratified by whether or not the
patient achieved the Cmax,ss threshold of 0.373 ng/ml
at the 8 mg/day dose are provided in Supplemen-
tary Tables 3A and 3B and Supplementary Figure 1.
Baseline clinical characteristics are also compared
according to co-medication status with AD-approved
drugs in Supplementary Table 3 C. While there is
substantial overlap in the distributions of intrinsic
factors, the most prominent trends are for subjects
with above-threshold Cmax,ss to be older and to
have lower creatinine clearance than those with sub-
threshold levels. Indeed creatinine clearance is the
most important predictor of whether or not a patient
achieves a parent MT Cmax,ss above the threshold
of 0.373 ng/ml at the 8 mg/day dose. The correlation
between Cmax,ss and creatinine clearance is shown in
Supplementary Figure 2. As shown in Supplementary
Figure 3A, the probability of achieving the Cmax,ss
B.O. Schelter et al. / LMTM Reduces AD Clinical Decline and Brain Atrophy 939
Fig. 4. Hill equation analysis of pharmacological activity of
LMTM on cognitive decline and brain atrophy over 65 weeks using
model-derived least squares mean and standard error estimates of
change over 65 weeks for clinical (a) and MRI volumetric (b) end-
points according to plasma concentration group (8 mg/day) or dose
(150–250 mg/day) split by co-medication status with AD-approved
drugs.
threshold is nearly 100% at the lowest observed value
of creatinine clearance (20 ml/min/1.73 m2) and falls
consistently as creatinine clearance increases such
that the probability is essentially zero at the highest
observed creatinine clearance (106 ml/min/1.73 m2).
Supplementary Figure 3B shows the percentage of
patients expected to have plasma levels above the
0.373 ng/ml threshold irrespective of creatinine clear-
ance over a range of total daily doses of LMTM given
in twice daily divided doses.
We have also investigated the most commonly used
non-AD-labelled concomitant medications as poten-
tial extrinsic factors influencing plasma concentration
(Supplementary Table 4). In patients receiving the
8 mg/day dose, the only class having a significant
effect is the antihypertensive/antiarrhythmic group of
drugs, with more patients than expected by chance
having subthreshold Cmax,ss levels. This too may be
linked to age and/or renal function, but the interaction
has not been investigated further.
DISCUSSION
We report the results of an exploratory post hoc
population PK analysis based on estimated steady
state plasma levels in 1,296 (1,162 with baseline
and post-baseline clinical and neuroimaging data)
out of 1,686 patients participating in either of two
Phase III trials of LMTM in mild to moderate AD.
The trials were designed and randomized to compare
doses in the range 150–250 mg/day with a dose of
8 mg/day thought to be inactive and used to mask
possible urinary discoloration. No differences were
found between 8 mg/day and any of the high doses
in the analyses of outcomes as randomized in either
of the two Phase III studies [35, 36]. We now report
that notwithstanding the lack of a dose-response for
the doses tested, there is an exposure-response at an
LMTM dose of 8 mg/day for change over 65 weeks on
the clinical ADAS-cog11 and ADCS-ADL23 scales,
and MRI measures of global brain atrophy (LVV
and WBV) based on estimated steady state plasma
concentration of parent MT. High doses produc-
ing plasma concentrations well above the threshold
required for activity are not associated with any addi-
tional benefit.
The relationship between dose and pharmacolog-
ical activity can be understood more readily within
the overall concentration-response space that we have
now been able to define. The lack of dose-response
comparing 8 mg/day with high doses in the range
150–250 mg/day is attributed to two main factors:
a steep concentration-response at the 8 mg/day dose
and an apparent plateau at substantially higher con-
centrations. Over the range of steady state plasma
concentrations 0.3–0.8 ng/ml, patients receiving the
8 mg/day dose differ systematically in the extent of
decline on clinical and neuroimaging outcomes at 65
weeks. Differences in plasma concentration at this
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Table 2
Pharmacological activity analysis based on a threshold Cmax,ss 0.373 ng/ml to define a proxy for placebo; modelled difference in change
from baseline for the respective endpoints
A) All patients, split by B) Patients receiving LMTM, 8 mg/day, split by
Cmax,ss 0.373 ng/ml Cmax,ss 0.373 ng/ml
Difference±SEM CI p Nlow- Nhigh- Difference±SEM CI p Nlow- Nhigh-
exposure exposure exposure exposure
ADAS-cog11 –2.66 ± 0.69 –4.02, –1.30 <0.0001 193 969 –3.41 ± 0.76 –4.89, –1.92 <0.0001 193 373
ADCS-ADL23 0.54 ± 0.94 –1.30, 2.38 0.5634 192 967 1.22 ± 1.01 –0.77, 3.21 0.2283 192 373
LVV (cm3) –1.52 ± 0.34 –2.18, –0.85 <0.0001 184 863 –1.76 ± 0.38 –2.50, –1.01 <0.0001 184 335
WBV (cm3) 3.55 ± 1.10 1.48, 5.61 0.0008 180 859 4.39 ± 1.18 2.07, 6.71 0.0002 180 332
dose are shown to be driven primarily by renal func-
tion as measured by estimated creatinine clearance.
Thus, patients with high creatinine clearance have rel-
atively lower steady state plasma levels of the drug
and vice versa. This is consistent with the fact that
70% of clearance of the drug has been shown to be
via the kidneys and that patients with mild to mod-
erate renal impairment have been confirmed to have
higher plasma levels in an independent Phase I study
in renally impaired subjects (unpublished observa-
tions).
Steady state concentrations in the range
0.3–0.8 ng/ml span a critical transition zone as
regards pharmacological activity on clinical and
neuroimaging endpoints. A recent study in minipigs
using twice daily oral dosing of LMTM mimicking
the regime and doses used in the Phase III trials has
shown that the brain:plasma ratio is approximately
20 : 1 for the parent MT moiety at 2–4 h post-dose
(unpublished observation). This compares with a
ratio of 0.15 : 1 for MTC [20], which explains the
large difference in dose required for pharmacological
activity of LMTM and MTC. The brain: plasma
ratio for LMTM also makes it possible to estimate
the steady state concentrations of LMT in the brain
as 6–16 ng/ml (0.021–0.056M) corresponding
to the range of 0.3–0.8 ng/ml in plasma. We have
reported recently that LMT blocks tau aggregation
in vitro at a tau:LMT molar ratio of 1 : 0.1 [21].
Therefore, the brain concentration of aggregated
tau at which LMT could theoretically have activity
is less than ∼0.6 nmol/g. We have previously
estimated the concentration of filamentous tau
to be approximately 0.1 nmol/g in hippocampus
(higher in entorhinal cortex and substantially lower
in neocortex) in AD patients with MMSE score of
approximately 20 units [41]. The concentration of
oligomeric tau in AD brain is approximately 20%
that of filamentous tau [42]. It is therefore plausible
that the minimum plasma concentration required
for pharmacological activity is determined substan-
tially by the activity of LMT as a tau aggregation
inhibitor.
In addition to the 8 mg/day dose having pharmaco-
logical activity in the majority of patients receiving
it, the other factor consistent with the lack of a dose-
response is that the pharmacological effects seen at
plasma concentrations in the range 4–21 ng/ml are no
greater than those seen in patients with a plasma con-
centration in the range 0.4–0.8 ng/ml. The estimates
derived from the Hill equation analysis are consistent
with treatment effects reaching a plateau at plasma
concentrations in the range 0.9–4.1 ng/ml (corre-
sponding to theoretical doses of 16–80 mg/day),
although no confirmatory data are available in this
intermediate range. It is common for drug responses
to plateau above the concentrations/doses required
for activity. What was unexpected for LMTM was that
the threshold for pharmacological activity is so much
lower than for MTC. We have previously reported
that the concentration-response for a motor effect
in an FTD tau transgenic mouse model with severe
tau aggregation pathology shows a concentration-
response up to a brain concentration of approximately
1M with no added benefit at higher concentrations
[26]. The mechanisms responsible for this plateau
are unknown, but could reflect a combination of lim-
itations in neuronal capacity available for clearing
the tau protein released by LMT from tau oligomers
or filaments, homeostatic responses to the activating
effects of LMTM [32] or negative effects on neu-
ronal function at high concentrations. For example,
the FDG-PET outcomes were found to be worse at the
200 mg/day dose than at the 8 mg/day dose in mild
AD [35].
An important feature of the concentration-
dependency relationships we report is the consistent
difference in the pharmacological activity of LMTM
alone or as add-on to approved symptomatic treat-
ments for AD. These differences are seen at identical
plasma concentrations and hence cannot be explained
by pharmacokinetic differences in the absorption,
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Fig. 5. Comparison of primary clinical (a, b) and MRI volumetric (c, d) endpoints for all patients: categorized by Cmax,ss above (“high
exposure”) or below (“low exposure”) parent MT threshold of 0.373 ng/ml.
distribution, or elimination of the drug. There
are two possible explanations. The first might be
that patients receiving symptomatic treatments have
more severe disease and progress more rapidly
than untreated patients, and that therefore smaller
treatment effects are achievable. Patients receiving
AD-approved treatments when they entered the tri-
als were somewhat more impaired at baseline than
those not receiving these treatments. However, the
concentration-response analyses we have presented
correct for the effects of baseline severity on rate
of progression and outcome at 65 weeks, so this
is unlikely to account for the difference. An alter-
native explanation, which seems more likely in the
light of recent studies, is that the difference is neu-
ropharmacological, since the same phenomenon can
be reproduced in a well-characterized tau transgenic
mouse model for AD [32]. Chronic pretreatment with
either a cholinesterase inhibitor or memantine atten-
uates or eliminates many of the treatment effects
seen when LMTM is given without such pretreat-
ment. Tau-dependent LMTM treatment effects that
are subject to interference by prior treatment with
AD-approved drugs include reversal of behavioral
deficits, effects on synaptic SNARE-complex pro-
teins, and increase in brain mitochondrial Complex
IV activity. Since these LMTM effects are not seen in
wild-type mice, they are likely to represent secondary
consequences of the primary action of LMTM on tau
oligomers in synaptic terminals and in mitochondria.
The MT moiety (given as MTC) has been reported
to affect dopaminergic function in mouse models
of Parkinson’s disease [43–45]. We have found that
LMTM increases hippocampal acetylcholine levels
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Fig. 6. Comparison of primary clinical (a, b) and MRI volumetric (c, d) endpoints in patients receiving LMTM, 8 mg/day: categorized by
Cmax,ss above (“high exposure”) or below (“low exposure”) parent MT threshold of 0.373 ng/ml and AChEI and/or memantine use status.
in both tau transgenic and wild-type mice, and that
this effect is also eliminated by pretreatment with a
cholinesterase inhibitor [32]. LMTM may therefore
have additional effects on neurotransmitter function
which contribute to clinical activity and are not
secondary to effects on tau pathology. The mecha-
nism responsible for the reduction or elimination of
LMTM effects in mice pretreated with AD-approved
drugs appears to be part of a general homeostatic
downregulation occurring in many neuronal systems
in the brain that compensates for the activating effects
of cholinesterase inhibitors and memantine. This
has the overall effect of attenuating multiple neu-
ropharmacological responses to LMTM, although the
primary effect on tau aggregation pathology remains
unaffected. The concentration-response profiles in
patients receiving LMTM as an add-on are similar in
form to those receiving LMTM alone, implying that
LMTM has concentration-dependent activity both as
monotherapy and as add-on to AD-approved treat-
ments, albeit with the estimated maximum treatment
effects seen clinically reduced by about half in the
add-on group. This reduction in activity persists at
high doses/concentrations of LMTM and is therefore
not competitive.
Given that the 8 mg/day dose of LMTM appears
to have pharmacological activity in the majority of
patients receiving it, the only way to derive an esti-
mate of the potential clinical treatment effects of
LMTM from the data currently available to inform
the design of a further placebo-controlled trial is to
define a subthreshold patient group with minimal
drug exposure as a proxy for placebo. The thresh-
old we have used is based on the lower limit of
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Table 3
Comparison of patients receiving LMTM, 8 mg/day, with Cmax,ss above or below the parent MT threshold of 0.373 ng/ml (A and B), and
comparison of patients receiving LMTM, 8 mg/day as monotherapy, with Cmax,ss above the parent MT threshold of 0.373 ng/ml with patients
receiving the same dose as add-on to AD-approved treatments and having Cmax,ss below the parent MT threshold of 0.373 ng/ml (C): modelled
difference in change from baseline for the respective endpoints categorized according to AChEI and/or memantine use status at baseline
A. LMTM, 8 mg/day, as monotherapy
Difference±SEM CI p Nlow-exposure Nhigh-exposure
ADAS-cog11 –2.60 ± 1.16 –4.88, –0.33 0.0251 33 67
ADCS-ADL23 0.46 ± 1.47 –2.43, 3.34 0.7552 32 67
LVV (cm3) –1.60 ± 0.46 –2.50, –0.70 0.0005 33 61
WBV (cm3) 2.76 ± 1.66 –0.49, 6.01 0.0966 32 61
B. LMTM, 8 mg/day, as add-on therapy
Difference±SEM CI p Nlow-exposure Nhigh-exposure
ADAS-cog11 –3.52 ± 0.78 –5.05, –2.00 <0.0001 160 306
ADCS-ADL23 1.32 ± 1.04 –0.71, 3.36 0.2016 160 306
LVV (cm3) –1.81 ± 0.39 –2.56, –1.05 <0.0001 151 274
WBV (cm3) 4.69 ± 1.21 2.32, 7.06 0.0001 148 271
C. Comparison of LMTM, 8 mg/day, low Cmax add-on versus high Cmax monotherapy
Difference±SEM CI p-value Nlow-exposure Nhigh-exposure
ADAS-cog11 –7.53 ± 1.22 –9.93, –5.13 <0.0001 160 67
ADCS-ADL23 6.14 ± 1.64 2.93, 9.34 0.0002 160 67
LVV (cm3) –3.15 ± 0.62 –4.37, –1.93 <0.0001 151 61
WBV (cm3) 11.54 ± 1.87 7.88, 15.21 <0.0001 148 61
quantitation of the plasma assay, namely 0.2 ng/ml.
According to this criterion, 35% of patients receiv-
ing the 8 mg/day dose of LMTM had subthreshold
plasma levels following their first dose on Day 1. We
used this percentage to define patients with the least
exposure to the drug with a steady state plasma con-
centration below a threshold of 0.373 ng/ml. Patients
with plasma levels above this threshold have sig-
nificantly less decline on ADAS-cog11, LVV, and
WBV over 65 weeks than patients with sub-threshold
plasma levels. Similar concentration-dependent dif-
ferences are seen if the analyses were restricted to
patients receiving 8 mg/day. Similar concentration-
dependent differences are also seen when patients
receiving LMTM alone or as add-on to symptomatic
treatments are analyzed separately. These differences
do not depend on the choice of a particular threshold,
since the same pattern of results was seen when the
median concentration at the 8 mg/day dose was used
as the threshold. They also cannot be accounted for
by measurable differences in severity, geography, or
AD-approved co-medications since these variables
are included in the analysis model. Further analyses
including age and sex as covariates did not impact on
the results.
The analyses we have presented provide the basis
for the design of a confirmatory placebo-controlled
trial in mild to moderate AD which is currently ongo-
ing at sites in US, Canada, and EU. The trial aims
to compare a dose of 16 mg/day with placebo. This
is expected to produce an estimated mean plasma
concentration of 0.88 ± 0.18 ng/ml, which is close
to the concentration required for the maximum pre-
dicted treatment effect of LMTM on cognitive and
neuroimaging outcomes. At this dose, all patients
are expected to have plasma concentrations above
the 0.373 ng/ml threshold irrespective of renal func-
tion. Because of the larger apparent treatment effect
in patients not receiving symptomatic treatments, the
study is being conducted with LMTM as monother-
apy in patients who have either discontinued or have
not started taking symptomatic treatments for AD.
There are important limitations in the inferences
which can be drawn from the present study. A post-
hoc concentration-response analysis of the kind we
have undertaken does not prove efficacy. It provides
a means of determining how pharmacological activ-
ity is related to plasma concentration, and hence
dose. However, pharmacological activity is not the
same thing as efficacy. Efficacy can be established
only by demonstrating a statistically significant effect
on prespecified outcomes in a suitable randomized
placebo-controlled trial. The analyses presented here
have served the purpose of informing the design of the
confirmatory placebo-controlled trial which is now
ongoing. A further limitation is that the steady state
plasma levels have been estimated from data available
following a first in-clinic dose using a pharmacoki-
netic model developed and qualified in separate Phase
I studies. This is a standard approach in population
PK and exposure-response analyses. Although anal-
yses incorporating actual steady-state plasma levels
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produced directionally similar results, the estimates
are less accurate. Such analyses still require the use
of a pharmacokinetic model to estimate drug expo-
sure, and this in turn requires accurate recording of
the time interval between the dose and the taking of
the blood sample. Patients and their study partners
are generally poor at reporting the time of taking the
last dose prior to clinic attendance. In the study now
ongoing, patients are required to take their treatment
in clinic on the days when PK samples are collected
in order to minimize this problem and to permit bet-
ter estimation of actual steady state plasma levels. It
should also be noted that the concentration-response
relationships seen for cognitive and neuroimaging
outcomes were much weaker for the ADCS-ADL
outcome. This is consistent with the functional out-
come having a larger standard deviation than the other
outcomes, although the difference taking account
of co-medication status with AD-approved drugs
remains significant on this outcome.
Conclusions and summary
The exposure threshold required for LMTM to
have pharmacological activity on brain structure and
function is much lower than anticipated based on
an earlier study with MTC. This is due to substan-
tially better brain uptake of the active LMT species.
The lack of difference in outcomes between 8 mg/day
and 150–250 mg/day we have reported previously
can be understood as being due to a combination of
activity of LMTM in the majority of patients receiv-
ing 8 mg/day and lack of additional activity at high
doses. The exposure-dependent relationships are sim-
ilar whether LMTM is taken alone or as add-on to
approved AD treatments, although the maximum pre-
dicted effect as add-on therapy is about half that for
LMTM taken alone irrespective of dose. A dose of
16 mg/day is predicted to be the minimum required
to ensure that all patients have plasma concentrations
in the range required for pharmacological activity and
to maximize this activity.
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